- Home
- XOMAP
as 11-11-2025 10:09am EST
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
| Founded: | N/A | Country: | United States |
| Employees: | 13 | City: | EMERYVILLE |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | N/A |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | N/A | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock News
XOMAP Breaking Stock News: Dive into XOMAP Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
Zacks
5 months ago
XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last?
GlobeNewswire
5 months ago
XOMA Royalty Declares Quarterly Preferred Stock Dividends
GlobeNewswire
6 months ago
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
Argus Research
6 months ago
Daily – Vickers Top Buyers & Sellers for 05/21/2025
Simply Wall St.
6 months ago
Results: XOMA Royalty Corporation Exceeded Expectations And The Consensus Has Updated Its Estimates
Simply Wall St.
6 months ago
XOMA Royalty First Quarter 2025 Earnings: Beats Expectations
Zacks
6 months ago
XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates
Compare XOMAP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.